Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT study of zelicapavir in healthy adults
NCT06601192Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zelicapavir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Time-matched, placebo-corrected change-from-baseline QTc based on the Fridericia correction. Started Jul 2024; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06601192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601192.